Albireo Pharma, Inc.
ALBO · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $41 | $8 | $10 | $13 |
| % Growth | 388.4% | -13.8% | -24.4% | – |
| Cost of Goods Sold | $1 | $0 | $2 | $0 |
| Gross Profit | $39 | $8 | $7 | $13 |
| % Margin | 96.7% | 100% | 77.1% | 100% |
| R&D Expenses | $83 | $77 | $46 | $32 |
| G&A Expenses | $0 | $42 | $23 | $18 |
| SG&A Expenses | $70 | $42 | $23 | $18 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $11 | -$15 | $2 | $1 |
| Operating Expenses | $163 | $105 | $71 | $51 |
| Operating Income | -$123 | -$96 | -$61 | -$38 |
| % Margin | -304.3% | -1,158.8% | -634.2% | -297.4% |
| Other Income/Exp. Net | $89 | -$11 | -$2 | -$8 |
| Pre-Tax Income | -$34 | -$108 | -$63 | -$46 |
| Tax Expense | $117 | $11 | $9 | $0 |
| Net Income | -$151 | -$119 | -$72 | -$46 |
| % Margin | -373% | -1,432.3% | -744.1% | -361.9% |
| EPS | -7.87 | -7.45 | -5.77 | -3.94 |
| % Growth | -5.6% | -29.1% | -46.4% | – |
| EPS Diluted | -7.87 | -7.45 | -5.77 | -3.94 |
| Weighted Avg Shares Out | 19 | 16 | 12 | 12 |
| Weighted Avg Shares Out Dil | 19 | 16 | 12 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $14 | $11 | $5 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$20 | -$96 | -$57 | -$38 |
| % Margin | -48.9% | -1,156.5% | -594.6% | -297.1% |